Drugs / US-APR2020
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT04913272 | Jun 2021 → Sep 2025 | chronic kidney disease | Kibow Pharma | Suspended | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2021-04-13 | Kibow Pharma | Regulatory Kibow Biotech Announces FDA Approval of IND to Initiate Phase II Clinical Trial of US-APR2020 to Treat Chronic Kidney Disease Stage IV kibowbiotech.com ↗
Kibow Biotech, Inc., a clinical-stage biotechnology company pioneering the discovery and development of probiotics and prebiotics (synbiotics) for the treatment of kidney diseases beyond gut health, today announced that the U.S. Food and Drug Administration (FDA) had approved the Company's Investigational New Drug Application (IND) for US-APR2020 to treat patients with Chronic Kidney Disease (CKD) stage IV. |
All press releases naming this drug 2 releases
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | US-APR2020 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04913272 ↗ |
| Known as | KT-301 | “KT-301 (formerly US-APR2020) is a live biotherapeutic (LBT) intended to restore the gut microbiome to improve the removal of uremic toxins in the bowel in CKD patients.” NCT04913272 ↗ |
| Modality | Other / unclassified | “KT-301 (formerly US-APR2020) is a live biotherapeutic (LBT)” NCT04913272 ↗ |
| Route | Oral | “will be administered KT-301 (formerly US-APR2020) orally” NCT04913272 ↗ |